David Westenberg

Maybe a couple on oncology. First, the field partnership, if you can maybe speak to early adoption there?

how should we think about test per patient right now and where it could go in the next 5 to 10 years?

Do you believe that could be a key part of consumer health? And then are there any strategies to participate in that market?

It looks like it contracted by about 5% over the last few years, and then government has kinda gone up. Is some of that LifeLab

on the collaboration with Google Cloud to streamline data management and you generate GenAI to personalize customer experience

How do you expect those acquisitions to enhance the revenue stream? And how should we think about as they lap the organic revenue growth

Can you talk about what's essentially been driving it between market growth share gains versus just higher utilization

whether or not they are gravitate toward 360 or a capital purchase

Are you seeing, at least the data I think is suggesting there might be a little bit more cats than dogs in the pet adoption trend?

over the longer term, I wanted to get your kind of thoughts on self-collection and cost of goods sold and margin.

could we see some investments from you over the next couple of years and some DTC efforts? And how should we think about the magnitude of that growth

How do you see that market shaking out over the next few years? I mean, currently, liquid and CGP NGS tend to be fairly oligopolistic

Can you talk about reimbursement or expectations on time lines and reimbursement? I know Invitae had reimbursement but it also had some IP fights

Do you believe that the health care system can effectively start to reimburse for really the challenges

can you just kind of remind us the normal seasonality in the business as we go through the year?

Can you clarify how much of the Q2 deterioration now is market contraction versus maybe some competitive pressure?

can you talk about some of the changes you can make in terms of pricing and strategy to maybe bundle with clinics or anything to kind of drive volume versus what you have seen in prior years?

are there any strategies that are to actively leverage and promote Cytopoint, the injectable alternative in order to maintain and potentially grow market share in the overall dermatology franchise

Amazon is, now selling some of the online drugs probably, I think it’s just singles right now, but maybe get a broad spectrum

Can you tell whether or not there is any potential backlogs or delays in the FDA?